Active Not Recruiting PHASE2 INTERVENTIONAL 3-arm NCT06505928

A Clinical Trial of Hepalatide for Injection in Patients With Chronic Hepatitis D (L47-HD-MN)

A Parallel-group, Randomized, Open-label Clinical Trial of Hepalatide for Injection in Patients With Chronic Hepatitis D.

Sponsor: Shanghai HEP Pharmaceutical Co., Ltd.

Conditions Hepatitis D

Interventions hepalatide

Updated 6 times since 2024 Last updated: Dec 16, 2025 Started: Dec 11, 2024 Primary completion: May 31, 2026 Completion: Jul 31, 2026

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT06505928, this PHASE2 trial focuses on Hepatitis D and remains ongoing. Sponsored by Shanghai HEP Pharmaceutical Co., Ltd., it has been updated 6 times since 2024, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.

Status Flow

Change History

6 versions recorded

Jan 2026 — Present [monthly]

Active Not Recruiting PHASE2

Status: Recruiting → Active Not Recruiting
Mar 2025 — Jan 2026 [monthly]

Recruiting PHASE2
Jan 2025 — Mar 2025 [monthly]

Recruiting PHASE2

Status: Not Yet Recruiting → Recruiting
Dec 2024 — Jan 2025 [monthly]

Not Yet Recruiting PHASE2
Sep 2024 — Dec 2024 [monthly]

Not Yet Recruiting PHASE2

▶ Show 1 earlier version

Aug 2024 — Sep 2024 [monthly]

Not Yet Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Shanghai HEP Pharmaceutical Co., Ltd.

Data source: Shanghai HEP Pharmaceutical Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Ulaanbaatar, Mongolia